Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tinengotinib (TT-00420) inhibits tumor growth and overcomes multidrug resistance in gastrointestinal cancers.

Molecular cancer therapeutics·2026
Same author

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.

Oncogene·2026
Same author

A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS-STING-type I IFN signaling in macrophages.

Nature cancer·2026
Same author

Optimizing Postoperative Management in Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter Retrospective Study.

Journal of gastric cancer·2026
Same author

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

British journal of cancer·2026
Same author

Surufatinib plus toripalimab for patients with advanced solid tumors and disease progression after prior immunotherapy: an open-label multi-cohort phase 2 trial.

Cancer immunology, immunotherapy : CII·2026

Related Experiment Video

Updated: Mar 6, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K

Allogeneic B7-H3-Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study.

Chang Liu1, Jiarui Li2, Dan Liu1

  • 1Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Early Drug Development Center, Peking University Cancer Hospital and Institute, Beijing, China.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 4, 2026
PubMed
Summary

This study shows that allogeneic B7-H3-targeted CAR-Vδ1T cell therapy (UTAA06) is safe for solid tumors but has limited efficacy due to immune rejection. Future strategies are needed to improve CAR-T cell persistence.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Related Experiment Videos

Last Updated: Mar 6, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Area of Science:

  • Oncology
  • Immunotherapy
  • Cell Therapy

Background:

  • Advanced solid tumors often lack effective treatment options.
  • Chimeric antigen receptor (CAR)-T cell therapy shows promise but faces challenges with allogeneic (
  • Purpose_of_the_Study
  • Main_Methods
  • Main_Results
  • Conclusions

Purpose of the Study:

  • Evaluate the safety, pharmacokinetics, and preliminary clinical activity of UTAA06, an allogeneic B7-H3-targeted CAR-Vδ1T cell therapy.
  • Assess UTAA06 in patients with pretreated, advanced B7-H3-positive solid tumors.

Main Methods:

  • Phase I, dose-escalation study (NCT06372236) enrolling ten patients with advanced solid tumors.
  • Patients received UTAA06 after lymphodepletion chemotherapy across three dose levels.
  • Primary endpoint was safety; secondary endpoints included pharmacokinetics and anti-tumor efficacy.

Main Results:

  • UTAA06 exhibited a manageable safety profile with no graft-versus-host disease (GvHD) and limited Grade 1 cytokine release syndrome (CRS).
  • One dose-limiting toxicity (Grade 3 pneumonitis) occurred at the lowest dose.
  • Biological activity was observed, including transient tumor marker reductions, but no objective responses by RECIST criteria.

Conclusions:

  • Allogeneic B7-H3-targeted CAR-Vδ1T cells represent a safe platform with low GvHD risk and biological activity in solid tumors.
  • Clinical efficacy was limited by reduced CAR-T cell persistence due to host immune rejection.
  • Future strategies must enhance cellular persistence to improve the therapeutic potential of this allogeneic approach.